Reuters logo
BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​
September 5, 2017 / 10:32 AM / 2 months ago

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

Sept 5 (Reuters) - Oramed Pharmaceuticals Inc

* ‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company’s novel oral insulin formulation​

* ‍At meeting, FDA gave guidance that regulatory pathway for submission of ORMD-0801, would be a biologics license application​

* In addition, FDA confirmed company’s ability to use insulin from different suppliers like HTBT in phase 3 study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below